Navigation Links
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
Date:2/8/2013

BOULDER, Colo., Feb. 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will present at the Leerink Swann Healthcare Conference in New York.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event:Leerink Swann Healthcare Conference Presenter:Ron Squarer, Chief Executive OfficerDate:Thursday, February 14, 2013Time:8:00 a.m. Eastern Time Location:The Waldorf Astoria, New York, NYWebcast:www.arraybiopharma.comAbout Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. During 2013, Array expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614.  Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis). Also, AstraZeneca recently announced a potential start of a Phase 3 trial with Array-invented selumetinib in non-small cell lung cancer during the second half of 2013.
For more information on Array, please go to www.arraybiopharma.com.

CONTACT: 

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
2. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
6. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
7. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
8. Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
9. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
10. PDL BioPharma Announces Departure of Finance VP
11. PDL BioPharma Announces 2013 Regular Quarterly Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... research and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money ... be packaged with the April edition of American Veterinarian™. , “We ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , ... pursue the recent RNA methylation “gold rush” with their established portfolio of optimized ... characteristics of N6-methyladenosine, or m6A , RNA methylation has received a new ...
(Date:3/27/2017)... Los Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... for men with prostate cancer, including all stages, is more than 95%. Once the ... drops drastically to less than 30%. To find out how to avoid this latter ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Harris Communications, ... of hearing, is bringing its latest products to the Deaf Seniors of America Conference, ... have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and ...
Breaking Medicine News(10 mins):